This was part of a letter written by David Cline, Unit Head of Clinical Priorities at the Scottish Government as part of a response to the Scottish Thyroid and Adrenal petition:
"In terms of the possibility of potency levels of T3 currently varying between
batches, the Medicines and Healthcare products Regulatory Agency (MHRA) have
responsibility across the UK for the licensing, supply and safety of medicines. In order to
allow them to follow up on whether or not there is a difference in potency levels between
current batches of T3 then it would be helpful if details could be supplied of the batch
numbers, expiry date, marketing authorisation holder and product licence for the
medicine. The Scottish Government would be happy to follow this up with MHRA if these
details can be supplied."